Digital Therapeutics (DTx) Market Forecasts to 2028 – Global Analysis By Product and Service Type (Device), Purchase Mode (Individual, Group Purchase Organization), Application (Preventive, Treatment/Care-Related) and By Geography

Digital Therapeutics (DTx) Market Forecasts to 2028 – Global Analysis By Product and Service Type (Device), Purchase Mode (Individual, Group Purchase Organization), Application (Preventive, Treatment/Care-Related) and By Geography

According to Stratistics MRC, the Global Digital Therapeutics (DTx) Market is accounted for $3.79 billion in 2021 and is expected to reach $22.51 billion by 2028 growing at a CAGR of 29.0% during the forecast period. Digital therapeutics provides evidence-based therapeutic interventions to patients. It is delivered through software programs and devices to prevent, manage, or treat a medical condition. The digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. The design, clinical validation, usability, and data security of digital therapeutics products are all based on advanced technology best practices.

Market Dynamics:

Driver:

Growing incidence of preventable chronic diseases

The high prevalence and incidence rate of chronic diseases is a major concern for healthcare systems across the globe. The treatment of patients with chronic diseases is a significant challenge, as psychosomatic or bio psychic factors very often influence these patients. As chronic diseases are often associated with high levels of uncertainty, patients need to change their behavior as part of a new self-care lifestyle. Furthermore, many chronic disorders and conditions are progressive, and their incidence increases with age. As a result, with significant growth in the global geriatric population, chronic disorders are expected to rise further in the coming years.

Restraint:

Patient data privacy concerns

In many countries, various health apps are deprived of appropriate approvals, leading to concerns of product & data quality, reliability in treatment decisions, patient privacy, security, and the responsible use of data. Digital therapeutics providers have access to patient information and are forbidden from sharing the information with anyone not involved in treating that patient. However, with the integration of data using digital tools, the patient’s data is at risk of being accessed by any healthcare professional not related to the patient’s treatment program.

Opportunity:

Strategic initiatives by manufacturers

Strategic initiatives practice supports companies undertaking the most important growth or expansion projects. While organizations are normally well-geared to manage the day-to-day aspects of business efficiently, major new strategic initiatives tend to be complex projects with multiple workstreams involved. The team helps clients maintain focus on business-as-usual functions by dexterously supporting the unique and complex task flows that accompany Greenfield integration or post-merger integration.

Threat:

Reluctance among patients to adopt digital therapeutics

Motivating people to use digital therapeutics and building their confidence is a major threat faced by digital therapeutics providers. While older and underserved populations show maximum susceptibility to diseases and the highest occurrence rates, they are the least likely to use digital therapeutics products due to low technology literacy levels. Furthermore, the limit of how much behavioural change will be observed with digital therapeutics is still undefined. The clinical validation and deployment of digital therapeutics are carried out on self-selected or volunteer patients; however, their effect on patients showing resistance is still unknown. Furthermore, it is unknown whether digital therapeutics can be sustained over longer periods; there is little information on total patient retention and long-term outcomes.

The treatment/care-related applications segment is expected to be the largest during the forecast period

The treatment/care-related applications are expected to have the largest share during the forecast period. This segment is attributed to the increasing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.

The business-to-business (B2B) segment is expected to have the highest CAGR during the forecast period

The business-to-business (B2B) segment is growing at the highest CAGR in the market. This is attributed to increasing alertness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.

Region with highest share:

North America is projected to hold the largest market share due to factors such as the influx of new start-ups, rising investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements.

Region with highest CAGR:

North America is projected to have the highest CAGR during the forecast period. This is attributed to the increase in the geriatric population, rise in incidences of chronic diseases, the surge in demand for wireless & portable systems, and availability of sophisticated reimbursement structure that aims in reducing expenditure.

Key players in the market:

Some of the key players profiled in the Digital Therapeutics (DTx) Market include 2Morrow, Inc., Akili Interactive Labs, Inc., Ayogo Health, BehaVR Inc, Better Therapeutics , Canary Health, Click Therapeutics, CogniFit Ltd., Cognoa, Hinge Health, Livongo, Mango Health, Inc., Mindable Health , Smartpatient , Omada Health, Pear Therapeutics, Propeller Health, Virta Health, Welldoc , and Wellthy Therapeutics.

Key developments:

In April 2021: Welldoc partnered with Dexacom. This partnership helped provide BlueStar with Dexcom G6 CGM as a single platform to people with Type 2 diabetes for improved health.

In March 2021: Pear Therapeutics partnered with Sprectrum Health Systems. Tufts Health Plan and Spectrum Health Systems announced collaboration with Pear Therapeutics to test FDA-approved digital therapeutics to help people with substance use disorders and improve their recovery journeys by delivering solutions for improved treatment access and care innovation journeys by delivering solutions for improved treatment access and care innovation.

In April 2020: Smartpatient partnered with “Around the Pill’ Solutions for pharmaceutical development. This partnership needs to be done to gain partnered products and developments to gain more customers and expanding the business.

In January 2020: Crossroads Treatment Centers collaborated with Pear Therapeutics to implement the company’s digital platform reSET-O to help patients with opioid abuse and addiction.

Product and Service Types Covered:
• Solutions/Software
• Device
• Service
• Hardware

Sales Channels Covered:
• Business-to-Consumer (B2C)
• Business-to-Business (B2B)

Purchase Modes Covered:
• Individual
• Group Purchase Organization

Applications Covered:
• Preventive Applications
• Treatment/Care-Related Applications

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances